Adocia announces that it has raised 2 million euros from its two main shareholders and a member of its management, and has signed an equity line of credit with Vester Finance.

The purpose of these financing operations is to strengthen the short-term cash position of 3 million euros, pending the signature of partnership agreements and receipt of milestone payments from Tonghua Dongbao.

To date, the Company has a cash position of 8.1 million euros, enabling it to finance its activities until August 2024, without taking into account the proceeds of this financing transaction and income from existing or future partnerships.

With the strengthened cash position of 3 million euros received on the signing of this transaction, the Company's cash horizon has been extended to November 2024, and extended to the third quarter of 2025 taking into account the use of the entire PACEO.

' The Company is still in exclusive negotiations with Sanofi for a global partnership on M1Pram, and expects two milestone payments of $10 million each, over the second half of 2024, linked to the progress of its two projects BioChaperone® Lispro and BioChaperone® Combo in partnership with Tonghua Dongbao ' says management.

Copyright (c) 2024 CercleFinance.com. All rights reserved.